Concretely: cystatin C · semaglutide.
I would like to define my thresholds before I have a result, for obvious reasons.
I want a plan with explicit stopping rules, not just steps.
How do I make this decision on evidence rather than on feel?
Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.
A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.
Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.
The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.
Baseline first, then a repeat under identical conditions. Everything else is secondary.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThis is answerable, and the answer is mostly about which tests rather than how many.
A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.
Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.
Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.
Keep the full report, not the number. You will need the units and the interval later.
The short version: a small, well-chosen panel with a baseline beats a large one without.
Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.
More usefully, haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.
Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.
Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.
One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.
edited 27 Mar 2026 by rae_oyelowo — clarified the distinction between purity and content
Standardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.
Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.
External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.
Research-use compounds are not approved for human use, and no panel makes that safer.
Decide the action for each result before you order the test.
Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.
Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.
Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.
The caveat is the population. Trial participants were screened, monitored and supported; the effect size in an unmonitored setting is not the trial effect size, and it is not obvious in which direction the difference runs.
Same laboratory, same time, same fasting state, or the comparison is not a comparison.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.